Sharing with us more on the above topic is Dr Jeffrey Kasher, Vice President, Eli Lilly and Company, United States. He will be presenting at Pharma Trials World Asia 2012, part of a series of conferences at the 5th Annual BioPharma Asia Convention 2012.
Dr Kasher, Ph.D., was named vice president and chief operating officer, global clinical development for Eli Lilly and Company in February 2007. He received a bachelor of science degree in chemistry from Franklin & Marshall College (Lancaster, Pa), a doctorate in pharmacology from the State University of New York (Syracuse) and a postdoctoral fellowship in physiology at Yale University School of Medicine.
Kasher joined Lilly in 1986 as a senior pharmacologist in the department of drug metabolism and disposition where he made numerous contributions to the discovery and development of projects in the infectious disease therapeutic area. In 1992, he was named manager of pharmaceutical project management. Dr Kasher had operational responsibility for the Zyprexa (olanzapine) heavyweight team from 1995 to 1998, successfully leading the late phase development, global submissions, and launches of the product. In 1998, he was named director of pharmaceutical products, where he helped establish Lilly's product team organization. Dr Kasher moved to Belgium in 2000 as the managing director for the research and development site in Mont Saint-Guibert. Upon his return to Indianapolis in 2003, he served as operations director and then executive director for discovery biology in Lilly Research Labs, leading the transformation of the division into therapeutically-focused drug hunting teams. Most recently, Dr Kasher served as the executive director of the osteoarthritis/rheumatoid arthritis platform team, leading the development of an integrated strategy for a portfolio of novel drug candidates.
Dr Kasher will be elaborating more on the below topics:
1. Exploring and comparing different partnership models to optimise the clinical trial cycle in Asia
2. Evaluating various therapeutic areas for maximum benefits when pursued in a partnership
3. Adapting your business strategy to address the patent cliff challenge as well as Asia's role in the strategy for increased R&D productivity